The initial discovery of the ErbB2 gene in a rat neuro/glioblastoma model in 1984 was soon followed by the uncovering of its implication in breast cancer pathophysiology and prognosis, laying the groundwork for novel directions in breast cancer treatment and commencing the era of targeted therapy in modern oncology [2,3]. Here, ERBB2 is linked to breast carcinoma.